Biodexa Pharmaceuticals is registering the resale of up to 10,950 ordinary shares represented by 219 American Depositary Shares by selling shareholders. The transaction concerns existing holder sales rather than a stated company fundraising, while the supplement identifies the securities and confirms their Nasdaq Capital Market listing under BDRX.

Key Highlights

  • The ordinary shares carry a nominal value of £0.000001 each.
  • The filing describes a resale by selling shareholders.
  • Biodexa’s American Depositary Shares trade on the NASDAQ Capital Market under BDRX.

Biodexa Pharmaceuticals Plc (NASDAQ: BDRX) is registering the resale of up to 10,950 ordinary shares represented by 219 American Depositary Shares by selling shareholders. The securities are covered by a prospectus supplement dated September 11, 2026. The stated transaction is a resale by selling shareholders. The ordinary shares have a nominal value of £0.000001 per share.

Resale Covers 219 ADS

The registered amount represents 10,950 ordinary shares in total, with those shares represented by 219 American Depositary Shares. Selling shareholders identified in the prospectus may resell the securities covered by the registration. The securities are ordinary shares represented by American Depositary Shares. Biodexa Pharmaceuticals’ prospectus supplement relates to the resale of those securities by the selling shareholders.

Selling Shareholders Named As Sellers

Selling shareholders are identified as the parties offering the registered securities. The transaction is structured around resale of the ordinary shares represented by the American Depositary Shares. The stated offering terms identify the share count and ADS representation. They do not state a public offering price, proceeds figure, Underwriting arrangement or expected closing date.

Prospectus Supplement Amends and Supplements Prospectus

The supplement amends and supplements the prospectus associated with Biodexa Pharmaceuticals’ registration statement. It incorporates information from the company’s interim-results report covering the six months ended June 30, 2026. The company’s Chief Executive Officer, Stephen Stamp, signed the related report on behalf of Biodexa Pharmaceuticals.

BDRX Listing Identified

The registered resale covers 219 ADS, corresponding to 10,950 ordinary shares. The filing identifies the specified securities for resale by selling shareholders.